Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 1, 2011, Pages 74-80

  Chung, Hyun Hoon ^a   Kim, Jae Weon ^a   Kang, Keon Wook ^b   Park, Noh Hyun ^a   Song, Yong Sang ^a   Chung, June Key ^b   Kang, Soon Beom ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Endometrial carcinoma; FDG PET CT; Recurrence; SUV

Indexed keywords

BARIUM SULFATE; FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79551525689     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1614-y     Document Type: Article

References (31)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
2. WT Creasman CP Morrow BN Bundy HD Homesley JE Graham PB Heller 1987 Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study Cancer 60 2035 2041 1:STN:280:DyaL1c%2FgtF2ltQ%3D%3D 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8 3652025
3. E Podczaski P Kaminski K Gurski C MacNeill JA Stryker K Singapuri, et al. 1992 Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery Gynecol Oncol 47 323 327 1:STN:280:DyaK3s7hsVKmsQ%3D%3D 10.1016/0090-8258(92)90134-5 1473745 (Pubitemid 23011412)
4. MS Carey GJ O'Connell CR Johanson MD Goodyear KJ Murphy DM Daya, et al. 1995 Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium Gynecol Oncol 57 138 144 10.1006/gyno.1995. 1115S0090-8258(85)71115-8 1:STN:280:DyaK2M3kslSksg%3D%3D 10.1006/gyno.1995.1115 7729725
5. CP Morrow BN Bundy RJ Kurman WT Creasman P Heller HD Homesley, et al. 1991 Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 40 55 65 1:STN:280:DyaK3M7hsFaitA%3D%3D 10.1016/0090-8258(91)90086-K 1989916
6. A Ayhan R Tuncer ZS Tuncer K Yüce T Küçükali 1994 Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases) Int J Gynecol Cancer 4 306 309 10.1046/j.1525-1438.1994.04050306.x 10.1046/j.1525-1438.1994.04050306.x 11578422
7. PG Rose 1996 Endometrial carcinoma N Engl J Med 335 640 649 1:STN:280:DyaK28zitVCqsQ%3D%3D 10.1056/NEJM199608293350907 8692240 (Pubitemid 26277956)
8. T Kurihara H Mizunuma M Obara K Andoh Y Ibuki T Nishimura 1998 Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma Gynecol Oncol 69 192 196 10.1006/gyno.1998.5018S0090-8258(98)95018-1 1:CAS:528:DyaK1cXksV2qsrk%3D 10.1006/gyno.1998.5018 9648586
9. EM Rohren TG Turkington RE Coleman 2004 Clinical applications of PET in oncology Radiology 231 305 332 10.1148/radiol.23120211852312021185 10.1148/radiol.2312021185 15044750
10. Y Anzai WR Carroll DJ Quint CR Bradford S Minoshima GT Wolf, et al. 1996 Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses Radiology 200 135 141 1:STN:280:DyaK283lslWmsA%3D%3D 8657901
11. M Schelling N Avril J Nährig W Kuhn W Römer D Sattler, et al. 2000 Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689 1695 1:STN:280:DC%2BD3c3islyjsw%3D%3D 10764429
12. HH Chung SK Kim TH Kim S Lee KW Kang JY Kim, et al. 2006 Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis Gynecol Oncol 103 165 170 10.1016/j.ygyno.2006.02. 016S0090-8258(06)00178-8 10.1016/j.ygyno.2006.02.016 16574205
13. HH Chung H Jo WJ Kang JW Kim NH Park YS Song, et al. 2007 Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence Gynecol Oncol 104 529 534 10.1016/j.ygyno.2006.09.009S0090-8258(06)00716-5 10.1016/j.ygyno.2006.09.009 17049971
14. T Belhocine C De Barsy R Hustinx J Willems-Foidart 2002 Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma Eur J Nucl Med Mol Imaging 29 1132 1139 10.1007/s00259-002-0878-2 1:CAS:528: DC%2BD38Xmt1Cgtb0%3D 10.1007/s00259-002-0878-2 12192557 (Pubitemid 34985357)
15. SY Ryu MH Kim SC Choi CW Choi KH Lee 2003 Detection of early recurrence with 18F-FDG PET in patients with cervical cancer J Nucl Med 44 347 352 12620999
16. PW Grigsby BA Siegel F Dehdashti J Rader I Zoberi 2004 Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome J Clin Oncol 22 2167 2171 10.1200/JCO.2004.09.035 10.1200/JCO.2004.09.035 15169804 (Pubitemid 41095151)
17. M Charron T Beyer NN Bohnen PE Kinahan M Dachille J Jerin, et al. 2000 Image analysis in patients with cancer studied with a combined PET and CT scanner Clin Nucl Med 25 905 910 1:STN:280:DC%2BD3M7islaksg%3D%3D 10.1097/00003072-200011000-00010 11079589
18. PG Kluetz CC Meltzer VL Villemagne PE Kinahan S Chander MA Martinelli, et al. 2000 Combined PET/CT imaging in oncology. Impact on patient management Clin Positron Imaging 3 223 230 10.1016/S1095-0397(01)00055-3 11378434
19. S Makhija N Howden R Edwards J Kelley DW Townsend CC Meltzer 2002 Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review Gynecol Oncol 85 53 58 1:STN:280:DC%2BD387pt1ejsQ%3D%3D 10.1006/gyno.2002.6606 11925120 (Pubitemid 34304010)
20. HH Chung WJ Kang JW Kim NH Park YS Song JK Chung, et al. 2007 Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings Eur J Nucl Med Mol Imaging 34 480 486 10.1007/s00259-006-0260-x 10.1007/s00259-006-0260-x 17089122 (Pubitemid 46426988)
21. HH Chung WJ Kang JW Kim NH Park YS Song JK Chung, et al. 2008 The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings Eur J Nucl Med Mol Imaging 35 1081 1088 10.1007/s00259-007-0687-8 10.1007/s00259-007-0687-8 18180917
22. NS Horowitz F Dehdashti TJ Herzog JS Rader MA Powell RK Gibb, et al. 2004 Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer Gynecol Oncol 95 546 551 10.1016/j.ygyno.2004.08.009S0090-8258(04)00627-423 10.1016/j.ygyno.2004.08.009 15581961
23. R Suzuki E Miyagi N Takahashi A Sukegawa A Suzuki I Koike, et al. 2007 Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer Int J Gynecol Cancer 17 890 896 10.1111/j.1525-1438.2007.00859.x 1:STN:280:DC%2BD2svhsFGktA%3D%3D 10.1111/j.1525-1438.2007.00859.x 17343574 (Pubitemid 47063323)
24. K Nakamura J Kodama Y Okumura A Hongo S Kanazawa Y Hiramatsu 2010 The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer Int J Gynecol Cancer 20 110 115 10.1111/IGC.0b013e3181c3a28800009577-201001000- 00018 10.1111/IGC.0b013e3181c3a288 20130510
25. T Saga T Higashi T Ishimori M Mamede Y Nakamoto T Mukai, et al. 2003 Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer Ann Nucl Med 17 197 203 10.1007/BF02990022 12846541
26. A Chao TC Chang KK Ng S Hsueh HJ Huang HH Chou, et al. 2006 18F-FDG PET in the management of endometrial cancer Eur J Nucl Med Mol Imaging 33 36 44 10.1007/s00259-005-1876-y 10.1007/s00259-005-1876-y 16167154 (Pubitemid 41785307)
27. K Kitajima K Murakami E Yamasaki Y Domeki Y Kaji S Morita, et al. 2009 Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT Eur J Nucl Med Mol Imaging 36 362 372 10.1007/s00259-008-0956-1 10.1007/s00259-008-0956-1 18931841
28. C Horiuchi M Tsukuda T Taguchi Y Ishiguro K Okudera T Inoue 2008 Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas Ann Nucl Med 22 693 698 10.1007/s12149-008-0162-z 1:CAS:528:DC%2BD1cXhsVyltrfN 10.1007/s12149-008-0162-z 18982472
29. CC Riedl T Akhurst S Larson SF Stanziale S Tuorto A Bhargava, et al. 2007 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases J Nucl Med 48 771 775 10.2967/jnumed.106.037291 10.2967/jnumed.106.037291 17475966 (Pubitemid 47604978)
30. TC Yen LC See CH Lai CW Yah-Huei KK Ng SY Ma, et al. 2004 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression J Nucl Med 45 22 29 1:CAS:528:DC%2BD2cXht1artLc%3D 14734665
31. AL Harris 2002 Hypoxia-a key regulatory factor in tumour growth Nat Rev Cancer 2 38 47 10.1038/nrc704 1:CAS:528:DC%2BD38XhvF2jtL4%3D 10.1038/nrc704 11902584